Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids

Qingmei Ye¹, Kai Liu¹, Qun Shen¹, Qingyue Li¹, Jinghui Hao², Fangxuan Han*¹ and Ren-Wang Jiang*³

¹Hainan General Hospital, Haikou, China. ²Jiaozuo Second People’s Hospital, Jiaozuo, China. ³Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, Jinan University, Guangzhou, China

Multidrug resistance (MDR) resulting from different defensive mechanisms in cancer is one of the major obstacles of clinical treatment. To circumvent MDR many reversal agents have been developed, but most of them fail in clinical trials due to severely adverse effects. Recently, certain natural products have been reported to overcome MDR, including flavonoids which are abundant in plants, foods, and herbs. The structure of flavonoids can be abbreviated as C6-C3-C6 (C for carbon), and further categorized into flavonoids, iso-flavonoids and neo-flavonoids, according to their structural backbones. Flavonoids possess multiple bioactivities, and a growing body of research has indicated that both flavonoids and iso-flavonoids can either kill or re-sensitize conventional chemotherapeutics to resistant cancer cells. Here, we summarize the research and discuss the underlying mechanisms, concluding that these flavonoids do not function as specific regulators of target proteins, but rather as multi-functional agents that negatively regulate the key factors contributing to MDR.

Keywords: multidrug resistance, natural products, flavonoids, overcome, cancer, drug discovery

INTRODUCTION

Multidrug resistance (MDR) is one of the major challenges in cancer treatment (1), which occurs in a short period of time during/after treatment, and may result in cross resistance to many other structurally and mechanically different chemotherapeutics (2). MDR may be due to different mechanisms, including (1) ATP-binding cassette (ABC) transporters that pump out chemotherapeutics (3), (2) the mutation of oncogenes that become resistant to former treatments (4, 5), (3) an evolving adaptation of cancer cells to the microenvironment (6, 7), (4) survived cancer stem cells (CSCs) that escape from conventional therapies (8, 9), and (5) activated cell growth factors as well as cell defense systems, etc.

As membrane-bound proteins, ABC transporters refer to 49 transporter proteins that are classified into seven subfamilies, ABCA to ABCG, that locate in the cell membrane and have diverse functions (10). ABC transporters have two nucleotide-binding domains (NBDs) which bind and hydrolyze ATP, and two trans-membrane binding domains (TMDs) which carry their substrates out of the cell (11, 12). By using ATP, ABC transporters work to transport their substrates across the cell membrane, and the substrates include building blocks/nutrition such as amino acids, sugars, lipids, vitamins, peptides, and certain proteins etc. Importantly, they can protect cells against xenobiotics, including some anti-cancer drugs (13). Higher expressions of these transporters, such as ABCB1 (also known as P-glycoprotein, P-gp), ABCG2 (also known as breast cancer resistant protein,
BCRP), and ABCC1 (also known as multidrug resistance-associated protein 1, MRP1), have closely participated in MDR as confirmed by studies from both the laboratory and the clinic (14, 15). The overexpression of ABC transporters may lead to the resistance of conventional chemotherapeutics, such as doxorubicin (Dox), paclitaxel, colchicine, etc., radiotherapy, and targeted therapies, such as imatinib (14).

Cancer cells may also adapt to the changed microenvironment, e.g., the increased oxidative stress, leading to MDR. Oxidative stress is defined as the phenomenon of imbalance between the production of reactive oxygen species (ROS) and antioxidant defenses, which plays a key role in the initialization of many diseases for their impacts on tissue damage (16). Oxidative stress also contributes to tumor development and responses to anticancer therapies (17). Generally, certain level of ROS may benefit cancer cell proliferation and DNA mutations, while high level ROS may be a lethal factor that finally induces cell death (18). Research has shown that ROS levels are higher in cancer cells and in resistant cancer cells due to chemotherapy or radiotherapy (17, 19). Accordingly, the corresponding antioxidant pathways that eliminate ROS are up-regulated during tumor initiation and progression, rendering them more vulnerable to further oxidative stress assaults (18, 20). Therefore, targeting oxidative stress is a promising strategy to overcome MDR in cancer.

Cancer cells that grow rapidly need more oxygen supply for their energy supply and signal transmission (21, 22). Tissue hypoxia occurs due to an inadequate amount of oxygen delivery or due to cancer cell metabolism re-programming, rendering cancer cells to adapt to less oxygen by up-regulating several key proteins, including hypoxia-inducible factor-1α (HIF-1α), HIF-2α (23). More importantly, hypoxia can trigger MDR by impacting the efficacy of anticancer drugs (24). Furthermore, hypoxia may also induce the expression of ABCB1 and ABCG2 that pump out intracellular chemotherapeutic agents (25, 26), a common MDR mechanism.

Cancer stem cells (CSCs), a subset of cells within the tumor, that possess the potential of self-renewal, differentiation and tumorigenicity, are thought to be the major cause of cancer therapy failure due to their chemoresistance and radioresistance (9, 27). CSCs are situated in the niche, which are mainly composed of fibroblasts and endothelial, mesenchymal and immune cells, playing pivotal roles in drug resistance (28). Therefore, the elimination of CSCs represents one promising strategy to overcome MDR.

The cell cycle, the mechanism of cell division, is composed by four phases: the G1 phase, during which a cell begins to grow in size to be ready to DNA synthesis; the S phase (synthesis), during which cell synthesizes DNA; the G2 phase, during which a cell continues to grow to be ready for mitosis; the M phase (mitosis), during which the cell stops growing and divides into two cells (29, 30). The cell cycle is driven by cyclin-dependent kinases (CDKs) which are regulated by cyclins (cyclin A-Y). Studies have shown that certain phases of the cell cycle exhibit resistance to chemotherapeutics (31, 32), and cancer cells that over-express CDKs and cyclins demonstrate resistance to conventional chemotherapeutics (33–35).

Autophagy, a self-degradative system in which cells undergo degradation of intracellular components, is important for the energy balance in response to nutrient stress (36, 37). During chemotherapy, autophagy works as a prosurvival and resistance mechanism; therefore, the inhibition of autophagy can re-sensitize MDR cells and enhance the cytotoxicity of chemotherapeutic agents (38).

Epithelial mesenchymal transition (EMT), a biologic process that polarized epithelial cells undergoes multiple biochemical changes to achieve mesenchymal cell phenotype including enhanced metastasis, invasiveness, drug resistance (39, 40), which play an important role in the morphogenesis of multicellular organisms (41).

Other key enzymes in cancer cells are also overexpressed to evade the cell death induction caused by chemotherapeutics. Signal transducer and the activator of the transcription (STAT) protein family (STAT 1-6) are intracellular transcription factors that mediate cellular differentiation, proliferation, hemapoiesis, and apoptosis by transmitting signals from the cell surface receptors to the nucleus (42). STAT3 plays a pivotal role in tumor growth and metastasis and it is activated and up-regulated in solid tumors and resistant cancers, suggesting it as a promising target to overcome MDR (43–45).

p53 (also known as TP53) is a classic tumor suppressor gene that induces cell cycle arrest and apoptosis (46). Usually, p53 is down-regulated or mutated in cancer cells, especially in the cancer cells of MDR (47).

Another key player, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), composed with five transcription factors, can bind to DNA sequences at promoter regions of responsive genes to regulate cellular processes such as DNA transcription, cytokine production, and cell survival (48). Activated NF-κB not only promotes tumor cell proliferation and apoptosis suppression, but it also induces EMT which facilitates distant metastasis and drug resistance (49, 50).

Various MDR reversal agents have been developed and some of them have entered into clinical trials, however, most of them failed due to severely adverse effects or because they suffered resistance in a short time (51, 52). Effective novel agents that surmount MDR remain an unmet clinical need.

Natural products are the major resource for new lead compound identification and new drug discoveries, which account for nearly 50% over the past three decades (53). Of all the versatile chemical structures, flavonoids are one of the most intensively studied. Flavonoids are abundant in plants, foods such as fruits and vegetables, as well as in traditional herbs (54–56). Importantly, many flavonoids have been applied in humans for nutrition supply and for certain disease treatment (57, 58), indicating their safety properties. Structurally, flavonoids are classified into three categories: flavonoids; iso-flavonoids; neo-flavonoids, as shown in Figure 1. Specifically, flavonoids have a backbone of 2-phenyl-1,4-benzopyrone, iso-flavonoids have a backbone of 3-phenyl-1,4-benzopyrone, and neo-flavonoids have a backbone of 4-phenyl-1,2-benzopyrone. To date, ~5,000 diverse flavonoids have been identified (59).

Flavonoids are usually termed as multi-targeting and multifunctional molecules, as they possess multiple bioactivities, such
as cardiovascular protective effects (60), nerve system protective effects (61), anti-aging (62), anti-inflammatory (63), anti-cancer (64), so on and so forth. More importantly, flavonoids (as summarized in Figure 2) have been found to kill resistant cancer cells or to re-sensitize conventional anti-cancer drugs to reverse MDR via the mechanisms discussed above, indicating their appealing potential in resistant cancer treatment. Here, we summarize these reports and discuss the analyzing of underlying mechanisms.

**MULTI-FUNCTIONAL FLAVONOIDs OVERCOME MDR IN CANCER**

**Flavonoids That Regulate ABC Transporters to Overcome MDR**

Many flavonoids, such as Chrysin, Baicalein, Kaempferol, Quercetin, Rutin, Icaritin, and iso-flavonoids, such as Genistein and Biochanin A, have been found to regulate ABCB1, ABCG2, ABCC1 and other transporters to reverse MDR.

**Chrysin**, 5,7-dihydroxyflavone, which presents in honey, propolis, and the passion flower *Passiflora caerulea* (65), exhibits various bioactivities, including anti-cancer effects as it is reported to inhibit aggressive anaplastic thyroid cancer cells (66) and drug resistant triple-negative breast cancer cells (TNBC) (67). Chrysin can inhibit ABCB1-mediated rhodamine 123 (an ABCB1 substrate) efflux on human breast cancer cells MDA-MB-231 (68). Chrysin may also regulate ABCG2-mediated nitrofurantoin transport on ABCG2-overexpressing human MCF-7 breast cancer cells by increasing the area under the curve (AUC) (69). Moreover, Chrysin sensitizes the ABCG2-transfected cells to mitoxantrone (an ABCG2 substrate) via stimulating ATPase (70).

**Baicalein**, 5,6,7-Trihydroxylavone, isolated from *Scutellaria baicalensis* and *Scutellaria lateriflora* (71), holds potential in treating breast cancer (72), colorectal cancer (73), bladder cancer (74), etc. Baicalein may reverse ABCB1-mediated MDR as shown on ABCB1 gene transfected Madin-Darby canine kidney II (MDCK II) cells (75). Baicalein induces apoptosis and autophagy and decreases ABCB1 and anti-apoptotic Bcl-xL expression levels on 5-fluorouracil (5-FU) and Epirubicin resistant hepatocellular carcinoma cells (Bel7402/5-FU). By inhibiting an ABCB1-mediated drug efflux, Baicalein (5 g/ml and 10 g/ml) increases the intra-cellular concentrations of rhodamine 123 and Epirubicin (76). Through this similar mechanism, Baicalein enhances the cytotoxic effects of docetaxel in anaplastic thyroid cancer 8505c cells (77), and paclitaxel in its resistant MCF-7/Tax cells and in an animal model (78).

**Apigenin**, 4′,5,7-Trihydroxyflavone, isolated from *Apium graveolens* (79), shows anti-cancer effects to human breast cancer (80), prostate cancer (81), and imatinib-sensitive and resistant chronic myeloid leukemia K562/IMA3 cells (82). One molecular docking study indicates that Apigenin binds to the NDBs of ABCB1 and ABCB5 (83). Apigenin inhibits ABCB1 expression and re-sensitizes docetaxel-resistant prostate cancer DU145 cells to docetaxel (84). Through down-regulating ABCB1, Apigenin (2, 8 μM) significantly enhances the efficacy of doxorubicin (Dox, an ABCB1 substrates) in its resistant MES-SA/Dx5 cells (85) and breast cancer cells (MCF7/ADR) (86).

**Acacetin**, O-methylated Apigenin, found in *Robinia pseudoacacia, Turneria diffusa*, and *Betula pendula* (87), exhibits anti-cancer effects in prostate cancer cells (88) and hepatocellular carcinoma (89) etc. Acacetin inhibits the activities and functions of both ABCB1 (90, 91) and ABCG2 (92). Through down-regulating ABCB1 in non-small cell lung cancer (NSCLC) cells, Acacetin decreases efflux of Dox by 59% and further increases accumulation of Dox inside the cells up to 55%, leading to synergistic cytotoxic effects (91). As an ABCG2 inhibitor, Acacetin potentiates the cytotoxicity of SN-38 and mitoxantrone (both are ABCG2 substrates) in ABCG2-transfected K562 (K562/BCRP) cells (92).

**Wogonin**, 5,7-dihydroxy-8-methoxyflavone, isolated from *Scutellaria baicalensis* (93), exhibits multiple anti-cancer effects to gastric cancer cells, lung cancer cells and glioma cancer cells (94–96). Wogonin appears to be an inhibitor of ABCB1 (97), and it suppresses the function of ABCB1 and increases the cellular content of etoposide in HL-60 cells (98). In Dox-resistant human myelogenous leukemia K562/A02 cells, Wogonin re-sensitizes Dox by inhibiting functional activity and expression of ABCB1 at both protein and mRNA levels (99).

**Kaempferol**, 3′,4′,5,7-tetrahydroxyflavone, a secondary metabolite found in many plants, plant-derived foods, and traditional medicines (100), possesses inhibitory activities to gastric cancer cells, lung cancer cells (101, 102), and tyrosine kinase inhibitor (TKI)-resistant lung cancer cell line H1993.
FIGURE 2 | Chemical structures of flavonoids and iso-flavonoids that have MDR reversal effects.

(103). Kaempferol can inhibit the efflux of ABCB1 via stimulating ATPase activity (104, 105). It is also an ABCG2 substrate and it suppresses ABCG2 up-regulation (106), indicating its potential as a reversal agent. Indeed, Kaempferol (20 µM) shows a synergistic efficacy with cisplatin in surmounting ovarian cancer OVCAR-3 cells, and the combination inhibits the mRNA levels of ABCC6 and cMyc (107).

Naringenin, 4’,5,7-Trihydroxyflavanone, present in many fruits, and herbs (108), exhibits inhibitory effects to prostate cancer cells and glioblastoma cells (109, 110). Naringenin may inhibit the efflux of ABCB1 (111) via interactions with the hydrophobic pocket of the transporter as confirmed by a docking study (111). Through this mechanism, Naringenin significantly enhances the cytotoxicity of daunomycin to resistant human breast cancer cell lines MCF-7/ADR cells (112).

Quercetin, found in many fruits, vegetables, leaves, and grains, has been used as a nutrition supply for many years (113). Quercetin has been reported to kill many types of cancer cells, including human breast cancer MCF-7 cells (114), NSCLC A549 cells (115), ovarian cancer cells (116), etc. Quercetin is able to block the function and expression of ABCB1 and ABCC1, ABCC2 (112, 117, 118). As tested in 5-FU resistant
human hepatocellular carcinoma BEL/5-FU cells, Quercetin inhibits the functions and down-regulates the expressions of ABCB1, ABCC1, ABCC2 (118). Quercetin is found to inhibit the pumping effects of these three transporters, evidenced by more intracellular accumulation of rhodamine-123 and Dox (118). On ABCB1 over-expressing and Dox resistant human breast cancer MCF-7/dox cells, Quercetin significantly enhances the antitumor activity of Dox, paclitaxel, and vincristine. The combined treatment of Dox, paclitaxel, and vincristine with Quercetin significantly down-regulates ABCB1 expression and eliminates breast cancer stem cells (119). Further studies also confirms the reversal effects of Quercetin (0.7 and 25–100 μM, respectively) in MCF-7/dox cells (120) and in gene-encoded ABCB1 overexpressing oral cancer KB/VCR cells (121).

Other flavonoids that regulate ABC transporters include Rutin, a quercetin glycoside that inhibits the pumping effects of ABCB1 and ABCG2 (117, 122), Fisetin, found in many that has been found to possess sensitizing effects to conventional chemotherapeutics cabazitaxel (123) and paclitaxel or arsenic trioxide in NSCLC (124), 3,3′,4,7-Tetrahydroxyflavone, found in many fruits and vegetables (125), inhibits the function of ABCB1 (85), as well as 8-Prenylarigenen (126), a prenylflavonoid phytoestrogen found in hops (Humulus lupulus) and beer (127), and a clinical drug candidate Icaritin (under clinical trials in China for treatment of hepatocellular carcinoma), both of which inhibit the efflux of ABCB1 and ABCG2 (128, 129).

In addition, there are two iso-flavonoids that regulate ABC transporters. Genistein, 4′,5,7-Trihydroxyisoflavone, found in a number of plants including lupin, fava beans, soybeans, is an angiogenesis inhibitor that exhibits anti-cancer activities (130). Genistein is also reported to be an inhibitor of ABCB1, ABCC2 (131, 132). As tested in ABCC2-transduced MDCK-II cells, Genistein can inhibit the transport of Danofloxacin, a substrate of ABCC2 (133). Other further applications to reverse MDR mediated by ABC transporters remain to be explored.

Biochanin A, 5,7-Dihydroxy-4′-methoxyisoflavone, found in soy, exerts certain anti-cancer effects (134, 135). Biochanin A is found to be an ABCG2 inhibitor, as it increases the accumulation and cytotoxicity of mitoxantrone in mitoxantrone resistant MCF-7 MX100 cells which over-express ABCG2 (136).

Flavonoids That Regulate Oxidative Stress to Overcome MDR

Many flavonoids are reported to either increase ROS or inhibit the antioxidant enzymes, exhibiting MDR reversing potential.

Baicalein significantly induces ROS production on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistant prostate cancer PC3 cells, leading to TRAIL sensitization. The ROS scavenger catalase prevents TRAIL sensitization, indicating it a ROS mediated mechanism (137).

Nrf2, a transcription factor, works with kelch-like ECH-associated protein 1 (Keap1) and the antioxidant response element (ARE) as a cytoprotective response to endogenous and exogenous stresses caused by ROS via the up-regulation of antioxidant proteins (138). A higher level of Nrf2 and its target proteins contributes in Dox resistance in BEL-7402/ADM cells (139). Chrysin suppresses Nrf2 at both protein and mRNA levels to BEL-7402/ADM cells, sensitizing the cells to Dox. Moreover, Chrysin also increases the intracellular concentration of Dox (139). Glutathione (GSH) is a peptide that significantly reduces the damage caused by toxic xenobiotics and ROS (140, 141). By depletion 50 to 70% of intracellular GSH within 24 h, Chrysin potentiates the cytotoxicity of curcumin (a natural occurring compound that kills cancer cells) to PC-3 cells and human leukemia cell line HL-60 cells (142). This effect is also found in non-small cell epithelial cancer cell lines A549, H157, H460, and H1975 (143). Co-treating with Chrysins (5–30 μM) significantly enhances the sensitivity of the cells to Dox as compared to Dox alone. Mechanistically, Chrysins may facilitate GSH efflux as demonstrated in Brechbuhl’s study (143).

Wogonin robustly induces ROS accumulation in A549 cells and further sensitize A549 cells to TRAIL-induced apoptosis in vitro and in vivo, which can be reversed by ROS scavenger butylated hydroxyanisole (BHA) and N-acetyl-L-cysteine (NAC) (144). Moreover, Wogonin suppresses nuclear translocation of Nrf2 by NF-κB inactivation and induces more intracellular ROS as shown in K562/A02 cells and in HepG2 cells (145, 146), enhancing the effects of Dox in K562/A02 cells. Apigenin also lowers the GSH level, which then increases ROS levels, resulting in cell death of ABCC1 over-expressing H69AR-drug selected and HeLa/ABCC1-transfected cells (147). Through similar mechanisms, Wogonin may enhance the efficacy of (1) cisplatin in cisplatin resistant HNC cells (149), (2) Dox in its resistant human myelogenous leukemia K562/A02 cells (99), and MCF-7/DOX cells (148).

Luteolin, 3′,4′,5,7-Tetrahydroxyflavone, which is abundant in leaves and aromatic flowering plants, possesses inhibitory effects to pancreatic cancer cells (149), colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells (150), etc. Luteolin is also able to inhibit Nrf2 markedly and enhance the cytotoxicity of cisplatin in cholangiocarcinoma KLU-100 cells (151). By inhibiting Nrf2 (152), luteolin may enhance the efficacy of (1) oxaliplatin in oxaliplatin-resistant colorectal cancer cell lines HCT116-ox and SW620-ox cells (153), (2) bleomycin, Dox in A549 cells (154), and Dox in MDA-MB 231 cells (155).

Other flavonoid that modulate ROS includes Galangin, purified from the Alpinia galangal root, exhibits collateral sensitivity (156), a phenomenon where one compound shows better inhibitory effects to resistant cancer cells over sensitive cells (157).

The iso-flavonoid Genistein and 7,3′,4′-trihydroxyisoflavone, one of the major metabolites of daidzein found in fruits, nuts, and soy-based food (158), also exhibits bioactivity to Nrf2 and ROS. Genistein down-regulates the level of methylation in the Keap1 promoter region, which inhibits the transcription of Nrf2 to the nucleus, resulting in the suppression of Nrf2-dependent antioxidant enzymes and up-regulation of ROS in A549 cells (159). Through this mechanism, Genistein significantly increases cell apoptosis in A549 cells when combined with radiation (159). Through the induction of ROS and by down-regulating ABC transporters ABCB1, ABCC1 and ABCC2, 7,3′,4′-trihydroxyisoflavone (25 μM), significantly increases the intracellular accumulation...
of epirubicin and attenuates epirubicin resistant in HeLa cells (160).

Flavonoids That Regulate Hypoxia to Overcome MDR

Many flavonoids are found to regulate hypoxia to reverse MDR. **Baicalein** suppresses the HIF-1α expression in 5-FU resistant gastric cancer AGS cells by inhibiting the hypoxia-induced Akt phosphorylation, which finally leads to re-sensitizing 5-FU (161).

**Wogonin** decreases the expression of HIF-1α in human colon cancer cell lines HCT116 by inhibiting the PI3K/Akt signaling pathway. Through this mechanism, Wogonin enhances the cytotoxicity of Dox, cisplatin, paclitaxel to HCT116 cells (162).

**Quercetin** is another flavonoid that regulates HIF-1α, which consequently re-sensitizes Dox to Dox resistant breast cancer MCF-7/dox cells (120), and 4T1 cells (163), cisplatin and etoposide to HCT116 cancer cells (164).

Flavonoids That Regulate CSCs to Overcome MDR

Many flavonoids have been shown to suppress the growth of CSCs. **Baicalein** may selectively re-sensitize CD133+ tumor initiating CSCs (isolated from human liver tumors which exhibit drug resistance properties) to certain chemotherapeutics (36). Baicalein inhibits the SAR1B GTPase which is necessary for autophagy, a way cancer cells apply to avoid cytotoxic effects induced by chemotherapeutics (36). Furthermore, Baicalein works synergistically with the mTORC1 inhibitor in a patient-derived xenograft model of hepatocellular carcinoma via elimination of CSCs (165).

On human CD44+ prostate CSCs (isolated from human PC3 cells) which confer MDR, **Apigenin** is able to significantly enhance cisplatin’s efficacy by down-regulating the mRNA expression of anti-apoptotic Bcl-2, sharpin and surviving, and up-regulating pro-apoptotic caspase-8 and p53 (166). On another two CSCs cells, glioblastoma multiforme U87MG and U373MG cells, Apigenin significantly suppresses the cell growth, clonogenicity, and invasiveness, three key factors that represent the self-renewal property of CSCs. Mechanically, Apigenin blocks the phosphorylation of c-Met and its down-stream targets, such as the transducer and activator of transcription 3 (STAT3), Akt and protein kinase mitogen-activated protein kinase (MAPK) (167).

**Wogonin** exhibits anti-CSCs effects, as shown on CD133 human osteosarcoma CSCs (168). Wogonin induces apoptosis, inhibiting the mobility by down-regulating the expression of metalloproteinidase-9, leading to a halt in its renewal ability (168).

Other flavonoids that regulate CSCs are **Luteolin** and **Quercetin**. Luteolin is able to eliminate the CD44+/CD49f+ CSCs isolated from TNBC via ribosomal S6 kinase inhibition (169). Quercetin may suppress the self-renewal property of pancreatic cancer stem-like cells which is gemcitabine resistant via targeting β-catenin, restoring the sensitivity of gemcitabine in vitro and in vivo (170). Quercetin also inhibits the breast CSCs (171), colorectal CSCs and restores the sensitivity of Dox (172).

Flavonoids That Regulate the Cell Cycle to Overcome MDR

Some flavonoids have been shown to regulate the cell cycle to overcome MDR.

The cyclin E2 mRNA and protein expression was higher in tamoxifen resistant MCF-7 cells compared with sensitive cells. **Luteolin** specifically inhibits the Cyclin E2 protein expression in resistant cells and exhibits a synergistic effect with tamoxifen (173).

By down-regulating cyclin D1, **Quercetin** significantly enhances the efficacy of Dox in TNBC cells (174), and cisplatin in ovarian carcinoma SKOV3 cells and osteosarcoma U2OS cells (175).

**Scutellarin**, an active flavone extracted from Erigeron breviscapus Hand-Mazz, down-regulates Cdc2, cyclin B1, two cell cycle related proteins, and induces G2/M arrest and apoptosis to PC3 cells, and restores the sensitivity of cisplatin (176).

Flavonoids That Regulate Autophagy to Overcome MDR

In Dox resistant BEL-7402/ADM cells, **Apigenin** significantly enhances the sensitivity of Dox, induces miR-520b expression and inhibits autophagy-related protein 7 (ATG7)-dependent autophagy in vitro and in hepatocellular carcinoma xenografts model (177).

Treatment of ovarian cancer cells with cisplatin may elevate poly [ADP-ribose] polymerase 1 (PARP-1), which is important for cell survival by regulating autophagy. **Leteolin** can inhibit PARP-1 at both the mRNA and protein level, and suppress autophagy, restoring the sensitivity to cisplatin (178).

Another flavonoid **Icaritin** can inhibit epirubicin-induced autophagy which may cause epirubicin resistance, and acts synergistically with epirubicin to suppress the proliferation of BT5637 and T24 cells (179).

Flavonoids That Regulate EMT to Overcome MDR

As shown in pemetrexed-resistant NSCLC A549-R, H358-R, H460-R cells, EMT pathway promotes the MDR profile. **Kaempferol** is able to inhibit EMT signaling, rendering the resistant cancer cells susceptible to pemetrexed (180).

Another study indicates that EMT contributes in paclitaxel-resistance in ovarian cancer X10 and X22 cells. **Luteolin** at non-cytotoxic dose can reverse EMT, and re-sensitize the two cells to paclitaxel (181).

Flavonoids That Regulate Critical Enzymes to Overcome MDR

**Chrysins** selectively decreases the STAT3 phosphorylation to A549 cells, and re-sensitizes A549 cells to TRAIL (182).

On cisplatin-resistant lung cancer A549/DDP cells, combination of **Galangin** and cisplatin suppresses the cell
proliferation through inhibiting p-STAT3 and anti-apoptotic Bcl-2 and increasing pro-apoptotic Bax and Bid. This combination also exhibits potency in mice xenograft models (183).

Similar results are also found by pretreatment of Quercetin which significantly enhances the cytotoxicity of cisplatin in an ovarian cancer cell line by suppressing STAT3 phosphorylation and Bcl-2. In a xenograft mouse model of ovarian cancer, Quercetin enhances the antitumor effect of cisplatin (184).

**p53**

Li et al. reported that a combination of Chrysin and cisplatin increases p53 phosphorylation and accumulation by activating ERK1/2 in HepG2 cells, leading to significant apoptosis, evidenced by the over-expression of pro-apoptotic proteins Bax, death receptor 5 and the inhibition of the anti-apoptotic protein Bcl-2 (185).

Apigenin is reported to elevate p53 and up-regulate certain pro-apoptotic proteins, which may increase cisplatin-induced DNA damage and apoptosis of A549 and H1299 cells (186).

Quercetin may potentiate 5-FU in 5-FU resistant HCT15 cells (which harbor a p53 mutation) by increasing p53 expression and activating the apoptotic mitochondrial pathway (187).

Through activating the extracellular signal-regulated kinases (ERK)-mediated p53 pathway, Scutellarin is capable of sensitizing A549/DDP cells to cisplatin in vitro and in vivo (188).

**NF-κB**

By decreasing the activity and of NF-κB, Fisetin increases the expression of death receptor TRAIL-R1, strengthening the apoptosis induction effects of TRAIL to TRAIL-resistant androgen-dependent LNCaP cells (50).

Genistein is able to suppress NF-κB, potentiate cisplatin, docetaxel, Dox or gemcitabine in various cancer cells including prostate, breast, lung, pancreatic and ovarian cancer cells (189–191). Similarly, genistein also enhances oxaliplatin in gemcitabine-resistant pancreatic cancer cells (192), gemcitabine in osteosarcoma cells, cisplatin in medulloblastoma cells (193), arabinoside in acute myeloid leukemia cells (194), and arsenic trioxide in human hepatocellular carcinoma cells in vitro and in vivo (195), suggesting it a promising reversal agent.

The activation of NF-κB contributes to TRAIL resistance of prostate cancer LNCaP and DU145 cells. Biochanin A significantly augments the cytotoxicity of TRAIL in these two cell lines, and it sensitizes the TRAIL-resistant LNCaP cells through NF-κB inhibition, leading to an up-regulated death receptor TRAIL-R2, and the disrupted mitochondrial membrane potential (196).

Tectorigenin, isolated from the flowers of Pueraria thunbergiana (197), exhibits re-sensitizing effects on paclitaxel-resistant ovarian cancer cells MPSC1(TR), A2780(TR) and SKOV3(TR) (198). Tectorigenin inhibits NF-κB nuclear translocation and its target genes, such as FLIP, XIAP, Bcl-2, Bcl-xL, and COX-2, all of which are known to be associated with MDR. Consequently, Tectorigenin enhances the inhibitory effect of paclitaxel in these three paclitaxel-resistant ovarian cancer cells (198).

**Flavonoids That Regulate Other Key Enzymes Regulated to Overcome MDR**

It should be noted that apart from the aforementioned three key players in MDR, flavonoids also regulate other enzymes, e.g., Fisetin and Genistein regulate Akt to suppress Irinotecan and Oxaliplatin resistant CPT11-LoVo cells in vitro and in vivo (199), and enhance the cytotoxicity of cisplatin in A549 cells (200), respectively. Fisetin decreases the phosphorylated
MAPK to increase the sensitivity of cisplatin-resistant A549-CR cells to cisplatin (201) and erlotinib-resistant lung cancer cells to erlotinib (202). **Apigenin** inhibits adenine nucleotide translocase-2 (ANT2) to enhance the efficacy of TRAIL to prostate cancer DU145 and LNCaP cells (203). **Luteolin** inhibits vaccinia-related kinase 1 (VRK1) to enhance the efficacy of cisplatin in esophageal squamous cell carcinoma (204). **Quercetin** suppresses the proliferation of tamoxifen resistant breast cancer TAMR-MCF-7 cells by inhibiting the expression of Pin1, vascular endothelial growth factor (VEGF), HIF as well as activator protein-1 (AP-1) (205). **Quercetin** also re-sensitizes enzalutamide to enzalutamide-resistant prostate cancer cells to in vitro and in vivo by inhibiting Androgen receptor splice variant 7 (AR-V7) (206). **Genistein** abolishes the increased cyclooxygenase-2 (COX-2) to 5-FU resistant HT-29 colon cancer cells (207) and induces the cleavage of Bid to TRAIL resistant

| Compound name | Functions | Application | References |
|---------------|-----------|-------------|------------|
| Chrysanthemum | ABC transporters regulation | Sensitizing mitoxantrone | (70) |
| Baicalin | ROS induction | Sensitizing Doc, paclitaxel | (137) |
| Apigenin | ROS induction | Sensitizing TRAIL | (77, 78) |
| Acacetin | ABC transporters regulation | Killing resistant CSCs | (64–66) |
| Wogonin | ABC transporters regulation | Sensitizing Doc | (91, 92) |
| Baicalein | ABC transporters regulation | Sensitizing S-FU | (68) |
| Apigenin | ROS induction | Sensitizing Dox | (162) |
| Kaempferol | ROS induction | Sensitizing cisplatin | (107) |
| Galangin | ABC transporters regulation | ROS induction | (109) |
| Naringenin | ABC transporters regulation | ABC transporters regulation | (157) |
| Luteolin | ABC transporters regulation | EMT suppression | (109) |
| Quercetin | ROS induction | ABC transporters regulation | (112) |
| Rutin | ABC transporters regulation | ABC transporters regulation | (113) |
| Fisetin | Cell cycle regulation | Sensitizing Dox, paclitaxel | (114) |
| Scutellarin | ABC transporters regulation | Cell cycle regulation | (169) |
| Icariin | ROS induction | Autophagy inhibition | (170, 172) |
| Genistein | ABC transporters regulation | Cell cycle regulation | (175) |
| Biochanin A | ABC transporters regulation | p53 inhibition | (181) |
| 7,3′,4′-Trihydroxyisoflavone | ABC transporters regulation | Sensitizing mitoxantrone | (182) |
| Tectorigenin | NF-κB inhibition | Sensitizing paclitaxel | (183) |

**TABLE 1** Summary of the flavonoids with MDR reversal effects and their application.
human hepatoma cells (208), exerting its sensitizing effects. Chrysin, Apigenin, Luteolin, Quercetin and Genistein, also regulates the ubiquitin-proteasome pathway to overcome MDR in various chemotherapeutic drugs (209).

Furthermore, Chrysin may inhibit the pro-inflammatory mediators including interleukin-6 (IL-6) and the aldo-keto reductases superfamily (AKR1C1/1C2) expression, re-sensitizing cisplatin and Dox in NSCLC (210).

Apigenin also targets Axl and Tyro3 receptor tyrosine kinase (211), and impacts mitochondrial membrane potential (212), antagonizes Mcl-1 upregulation (213), or acts as an anti-estrogen and a protein kinase inhibitor (214) to sensitize certain chemotherapeutics.

Kaempferol may also enhance the efficacy of TRAIL in human ovarian cancer cells OVCAR-3 and SKOV-3 cells (215), and U251 and U87 glioma cells (216) via JNK/ERK-CHOP pathway and induction of proteasomal degradation of survivin, respectively.

Wogonin may also regulate AKR1C1/1C2 (210), and tumor necrosis factor-α (217). Wogonin increases Dox sensitivity through the down-regulation of the IGF-1R/AKT signaling pathway in human breast cancer (218), and increases the activity of sorafenib to human hepatocellular carcinoma cells by potentiating apoptosis and inhibiting autophagy (219).

Quercetin may potentiate the effect of fludarabine and ABT-737 against CLL via Mcl-1 inhibition (220), enhance the efficacy of (1) Dox in the Dox resistant prostate cancer (PC3) cell line (PC3/R) by down-regulating c-met (221) and Dox resistant human leukemic MDR K562/ADR cells by regulating JNK/MAPK (222), (2) TRAIL to pancreatic cancer cells through JNK-mediated cFLIP turnover (223), (3) tamoxifen in tamoxifen-resistant breast cancer cell line (MCF-7Ca/TAM-R) by up-regulating ERα and down-regulating Her-2 (224), etc.

**DISCUSSION AND FUTURE PERSPECTIVE**

An increasing body of studies have suggested that through single or combinational administration, flavonoids, and iso-flavonoids may work as sensitizing agents. While the major issue of mechanism study of flavonoids is the lack of specific targets and their acting mechanisms in surmounting, resistant cancer cells are still not understood properly (55). Currently, studies like those discussed above indicate that these flavonoids exert their anticancer efficacy through multiple mechanisms, and multiple targets, and it’s quite clear that certain flavonoids may overcome MDR by regulating various aspects that contribute to MDR. Therefore, they could be characterized as multifunctional natural compounds rather than multi-targeting agents (54, 105, 225, 226).

Flavonoids tend to target lipid bilayers and modify the membrane physicochemical properties to exert their bioactivities (227–230). As demonstrated in Ingólfsson et al.’s study, phytochemicals of different structures (polyphenols including flavonoid) could alter lipid bilayer properties as they localized on the bilayer/solution interface. Through a similar action, they also regulated bio-functions of diverse membrane proteins, suggesting that their actions may be due to the common, membrane bilayer-mediated mechanism (231). Therefore, we conclude that flavonoids do not function as specific regulators of target proteins, but rather as multi-functional agents that negatively regulate the key factors contributing to MDR as well as to other diseases.

To reverse MDR, these flavonoids may regulate many targets. First, the flavonoids may regulate ABC transporters, such as ABCB1, ABCG2, ABCC1, etc. They not only inhibit the efflux effects of these transporters to many conventional chemotherapeutics, but also inhibit the expressions. Docking studies indicate that they may bind to NBDs of ABCB1 (83). To date, no ABC transporter regulators have been approved by the FDA because of severe adverse effects. Natural products hold promise to be of lower toxic agents, given that many of the flavonoid regulators already serve as dietary supplements.

Second, as polyphenolic compounds, many flavonoids may work as ROS modulators (18) as they affect the status of ROS level in cancer cells (232). Under different dose, they may work either as ROS scavengers or inducer. To overcome MDR, they preferably work as inducers which induce more ROS production that can reach to the toxic threshold to activate apoptosis (18). Major players in maintaining balanced ROS in cells include Mrf2, GSH, both of which can be inhibited by certain flavonoids to exert their re-sensitizing effects.

Third, they may also regulate HIFs, cell cycle, CSCs, autophagy, and critical enzymes such as STAT3, p53, and NF-κB, confirming their multi-functional property as summarized in Figure 3 and Table 1.

Furthermore, certain flavonoids exhibit collateral sensitivity, a phenomenon where one compound shows selectivity to kill resistant cancer cells over sensitive cells (157), such as Galangin and Chrysin (156), apigenin dimer (234), and another flavonoid desmosdumotin B (235), making the flavonoids more appealing agents in treating resistant cancers.

In addition, some of these flavonoids are now under clinical trials to treat certain cancers, such as Apigenin (NCT03139227), Quercetin (NCT03476330, NCT02989129, NCT01912820, NCT01538316), Icaritin (NCT01278810, NCT01972672, NCT02496949). Further positive results will surely entice more researchers to develop them as drug candidates, e.g., MDR reversal agents.

One issue in this research is that most studies are conducted in vitro, so further in vivo studies are warranted. Given that many of the flavonoids are used as ingredients in dietary supplements, their anticancer/sensitizing efficacy could be more readily determined in humans (236–238). The natural products in flavonoids represent novel treatment strategies to overcome MDR in cancer, and structural modifications of these compounds should be of interest for medicinal chemists. Indeed, many flavonoids derivatives have been developed to suppress resistant cancer cells, such as Chrysin acyl derivatives against drug-resistant human cancer cells (MES-SA/DX5, LoVo/DX) (239), nitro Genistein derivatives modified by nitro groups against cisplatin-resistant human ovarian cancer A2780 cells (240),...
Quercetin-glutamic acid conjugate (241), and apigenin-based flavonoid dimer (242) against P-gp overexpressing cancer cells, selenium-containing Chrys and Quercetin derivatives against cisplatin resistant cancer cells (243), Quercetin-3-methyl ether against lapatinib-resistant breast cancer cells (244), etc. These studies provide crucial information for new drug discoveries based on flavonoids.

CONCLUSION

Dietary natural flavonoids possess multiple bioactivities including anti-cancer and chemo-sensitizing effects. Studies show that they inhibit certain ABC transporters, antioxidant enzyme Nrf2 and its related enzymes and regulate HIFs, CSCs, autophagy, EMT, etc., to exert their sensitizing effects, suggesting that they are multi-functional molecules.

REFERENCES

1. Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. *Biotechnol Adv.* (2013) 31:1397–407. doi: 10.1016/j.biotechadv.2013.06.004
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottsman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov.* (2006) 5:219–34. doi: 10.1038/nrd1984
3. Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. *Drug Resist Updat.* (2016) 27:14–29. doi: 10.1016/j.drup.2016.05.001
4. Xue M, Cheng J, Zhao J, Zhang S, Jian J, Qiao Y, et al. Outcomes of 219 chronic myeloid leukemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations. *Int J Lab Hematol.* (2019) 41:94–101. doi: 10.1111/ijlh.12928
5. Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, et al. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. *Ann Hematol.* (2013) 92:179–83. doi: 10.1007/s00277-012-1591-2
6. Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. *Drug Resist Updat.* (2015) 23:69–78. doi: 10.1016/j.drup.2015.08.004
7. Yeldag G, Rice A, Del RHA. Chemoresistance and the self-maintaining tumor microenvironment. *Cancers.* (2018) 10.E471. doi: 10.3390/cancers10120471
8. Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance driven by cancer stem cells and their niche. *Int J Mol Sci.* (2017) 18:E25274. doi: 10.3390/ijms18122574
9. Koren E, Fuchs Y. The bad seed: cancer stem cells in tumor development and resistance. *Drug Resist Updat.* (2016) 28:1–12. doi: 10.1016/j.drup.2016.06.006
10. Vasilou V, Vasilou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. *Hum Genom.* (2009) 3:281–90. doi: 10.1186/1479-7363-3-281
11. Beis K. Structural basis for the mechanism of ABC transporters. *Biochem Soc Trans.* (2015) 43:889–93. doi: 10.1042/BST20150047
12. Locher KP. Review. Structure and mechanism of ATP-binding cassette transporters. *Philos Trans R Soc Lond B Biol Sci.* (2009) 364:239–45. doi: 10.1098/rstb.2008.0125
13. Fletcher JL, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. *Drug Resist Updat.* (2016) 26:1–9. doi: 10.1016/j.drup.2016.03.001

AUTHOR CONTRIBUTIONS

QY, FH, and R-WJ conceived the topic. QY, KL, QS, QL, JH, FH, and R-WJ wrote the paper.

FUNDING

This research was funded by the Hainan Provincial Natural Science Foundation of China (Grant number: 817307).

ACKNOWLEDGMENTS

The authors would like to thank everybody involved in this review, especially Chunxin Huang, Lixin Deng, and all other colleagues for their helpful discussions and input.

14. Kathawala RJ, Gupta P, Ashby CJ, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug Resist Updat.* (2015) 18:1–17. doi: 10.1016/j.drup.2014.11.002
15. Caetano-Pinto P, Jansen J, Assaraf YG, Masereeuw R. The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. *Drug Resist Updat.* (2017) 30:15–27. doi: 10.1016/j.drup.2017.01.002
16. Betteridge DJ. What is oxidative stress? *Metabolism.* (2000) 49:3–8. doi: 10.1016/S0026-0495(00)80077-3
17. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov.* (2013) 12:931–47. doi: 10.1038/nrd4002
18. Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. *Drug Resist Updat.* (2018) 41:1–25. doi: 10.1016/j.drup.2018.11.001
19. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species carcinogenic emerging approach for cancer therapy. *Apoptosis.* (2017) 22:1321–35. doi: 10.1007/s10495-017-1424-9
20. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discov.* (2009) 8:579–91. doi: 10.1038/nrd2803
21. Ytersian SK, Tveitars MK, Lu N, Engelser A, Reed RK, Garmann-Johnsen A, et al. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. *PLoS ONE.* (2017) 12:e0183254. doi: 10.1371/journal.pone.0183254
22. Cui Q, Yang Y, Ji N, Wang JQ, Ren L, Yang DH, et al. Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. *Future Med Chem.* (2019) 11:323–36. doi: 10.4155/fmc-2018-0403
23. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. *Semin Oncol.* (2001) 28:29–35. doi: 10.1053/sonc.2001.09597-7754(01)09210-6
24. Wang P, Wan W, Xiong S, Wang J, Zou D, Lan C, et al. HIF1α regulates glioma chemosensitivity through the transformation between differentiation and dedifferentiation in various oxygen levels. *Sci Rep.* (2017) 7:7965. doi: 10.1038/s41598-017-06086-2
25. Badowska-Kozakiewicz AM, Sobol M, Patera J. Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. *Arch Med Sci.* (2017) 13:1303–14. doi: 10.5114/ams.2016.62723
26. He X, Wang J, Wei W, Shi M, Xin B, Zhang T, et al. Hypoxia regulates ABCG2 activity through the activation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. *Cancer Biol Ther.* (2016) 17:188–98. doi: 10.1089/cmb.2016.1139228
27. Sotiropoulou PA, Christodoulou MS, Silvani A, Herold-Mende C, Passarella D. Chemical approaches to targeting drug resistance in cancer stem cells. *Drug Discov Today.* (2014) 19:1547–62. doi: 10.1016/j.drudis.2014.05.002
Arora L, Kumar AP, Arfuso F, Chng WJ, Sethi G. The role of Ras and NF-kappaB in drug resistance in HeLa2/ADM cells. Int J Oncol. (2015) 46:2029–38. doi: 10.3892/ijo.2015.2925

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev. Cancer. (2018) 18:452–64. doi: 10.1038/s41568-018-0005-8

Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. (2016) 79:629–61. doi: 10.1039/acsnatprod.5b01055

Raffa D, Maggio B, Raimondi MV, Plescia F, Daidone G. Recent discoveries of anticancer flavonoids. Eur J Med. (2017) 142:213–28. doi: 10.1016/j.ejmech.2017.07.034

Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. (2015) 6:547. doi: 10.1017/jns.2016.41

Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A, et al. Flavonoids in cancer and apoptosis. Cancers. (2011) 3:118. doi: 10.3390/cancers11001028

Shou JW, Zhang RR, Wu HY, Xia X, Nie H, Jiang RW, et al. Isolation of novel biflavonoids from Cardioicrum giganteum seeds and characterization of their antitussive activities. J Ethnopharmacol. (2018) 222:171–8. doi: 10.1016/j.jep.2018.05.003

Rodriguez-Mateos A, Vazouz D, Krueger CG, Shammunagayyam D, Reed J, Calani L, et al. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compound: an update. Arch Toxicol. (2014) 88:1803–5. doi: 10.1007/s00204-013-1303-7

Pietta PG. Flavonoids as antioxidants. J Nat Prod. (2000) 63:1035–42. doi: 10.1021/np9904509

Mozaffarian D, Wu J. Flavonoids, dairy foods, and cardiovascular and metabolic health: a review of emerging biologic pathways. Circ. Res. (2018) 122:369–84. doi: 10.1161/CIRCRESAHA.117.309008

Mattias I, Buosi AS, Gomes FC. Functions of flavonoids in the central nervous system: astrocytes as targets for natural compounds. Neurochem Int. (2016) 95:85–91. doi: 10.1016/j.neuci.2016.01.009

Schagen SK, Zampeli VA, Makrantoniaki E, Zouboulis CC. Discovering the link between nutrition and skin aging. Dermatocedocrinol. (2012) 4:298–307. doi: 10.1002/dcr.22876

Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. (2010) 69:273–8. doi: 10.1017/S003266031000016X

Hosseinimehr SJ. Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today. (2010) 15:907–18. doi: 10.1016/j.drudis.2010.09.005

Miani R, Natevan V, Chrysin: sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry. (2018) 145:187–96. doi: 10.1016/j.phytochem.2017.09.016

Yu XM, Phan T, Patel PN, Jasksa-Sztul R, Chen H. Chrysins activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer-Am Cancer Soc. (2013) 119:774–81. doi: 10.1016/j.ccr.2014.09.022

Yang B, Huang J, Xiang T, Yin X, Luo X, Huang J, et al. Chrysins inhibit metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J Appl Toxicol. (2014) 34:105–12. doi: 10.1002/jat.2941

Molnar J, Maggio B, Raimondi MV, Plescia F, Daidone G. Recent discoveries of anticancer flavonoids. Eur J Med. (2017) 142:213–28. doi: 10.1016/j.ejmech.2017.07.034
Flavonoids

71. Li-Weber M. New therapeutic aspects of flavonoids: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalin and Baicalein. Cancer Treat Rev. (2009) 35:57–68. doi: 10.1016/j.ctrv.2008.09.005

72. Zhao X, Qu J, Liu X, Wang J, Ma X, Zhao X, et al. Baicalin suppress EMT of breast cancer by mediating tumor-associated macrophages polarization. Am J Cancer Res. (2018) 8:1528–40.

73. Chen Z, Hou R, Gao S, Song D, Feng Y. Baicalin inhibits proliferation activity of human colorectal cancer cells HCT116 through downregulation of Erzin. Cell Physiol Biochem. (2018) 49:2035–46. doi: 10.1159/000493714

74. Jiang L, Song H, Guo H, Wang C, Lu Z. Baicalin inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106. Biomed Pharmacother. (2018) 107:1583–90. doi: 10.1016/j.biopha.2018.08.107

75. Ferreira A, Rodrigues M, Fortuna A, Falcao A, Alves G. Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: an in vitro evaluation with focus on anti-epileptic drugs. Food Res Int. (2018) 103:110–20. doi: 10.1016/j.foodres.2017.10.010

76. Li J, Duan B, Guo Y, Zhou R, Sun J, Bie B, et al. Baicalin sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. Biomed Pharmacother. (2018) 98:806–12. doi: 10.1016/j.biopha.2018.01.002

77. Park CH, Han SE, Nam-Goong IS, Kim YI, Kim ES. Combined effects of baicalin and dactoxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the ERK and Akt/mTOR Pathways. EndocrinoMetab. J. (2018) 33:121–32. doi: 10.3833/Emj.2018.33.1.121

78. Meng L, Xia X, Yang Y, Ye J, Dong W, Ma P, et al. Co-encapsulation of paclitaxel and baicalin in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition. Int J Pharm. (2016) 513:8–16. doi: 10.1016/j.ijpharm.2016.09.001

79. Ko FN, Huang TF, Teng CM. Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochim Biophys Acta. (1991) 1115:69–74. doi: 10.1016/0304-4165(91)90013-7

80. Bauer D, Redmon N, Mazzio E, Soliman KF. Apigenin inhibits TNFα/Lt-1-induced CCL2 release through JNK-epson signaling in MDA-MB-231 human breast cancer cells. PLoS ONE. (2017) 12:e017558. doi: 10.1371/journal.pone.0175558

81. Erdogan S, Doganlar O, Doganlar ZR, Sertas R, Turkekul K, Dirdikib I, et al. The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-kappaB signaling. Life Sci. (2016) 162:77–86. doi: 10.1016/j.lfs.2016.08.019

82. Solmaz S, Adan GA, Cincin B, Ozdogu H, Boga C, Cakmakoglu B, et al. Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells. Nutr Cancer. (2014) 66:599–612. doi: 10.1080/01635581.2014.890499

83. Sreed M, Radioglu O, Khalid H, Sugimoto Y, Effert T. Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. J Nutr Biochem. (2015) 26:44–56. doi: 10.1016/j.jnutbio.2014.09.008

84. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, et al. Inhibition of ABCB1 expression overcomes acquired multidrug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRPI expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol. (2014) 92:220–34. doi: 10.1016/j.bcp.2014.09.008

85. Hakkinen SK, Karlampl SO, Heinonen IM, Mykkanen HM, Torronen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem. (2015) 63:45–62. doi: 10.1021/jf503094p

86. Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of the constituents from damiana (Turnera diffusa) by flavonoids and honokiol in vitro. Molecules. (2018) 23:317–24. doi: 10.3390/molecules23013171
107. Luo H, Daddysman MK, Rankin GO, Jiang BH, Chen YC. Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int. (2010) 10:16. doi: 10.1186/1475-2867-10-16

108. Du G, Jin L, Han X, Song Z, Zhao H, Liang W. Naringenin potent immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res. (2009) 69:1205–12. doi: 10.1158/0008-5472.CAN-08-3393

109. Gumushan AH, Akgun T. Naringenin inhibits prostate cancer metastasis by blocking voltage-gated sodium channels. Biomed Pharmacother. (2018) 106:770–5. doi: 10.1016/j.biopha.2018.07.008

110. Stompor M, Uram L, Podgorski R. In vitro effect of 8-prenylnaringenin and naringenin on fibroblasts and glioblastoma cells-cellular accumulation and cytotoxicity. Molecules. (2017) 22:1092. doi: 10.20944/preprints201706.0071.v1

111. Rauf A, Uddin G, Raza M, Ahmad B, Jehan N, Siddiqui BS, et al. Inhibition of P-glycoprotein by Flavonoids from Pistacia integerrima. Asian Pac J Cancer Prev. (2016) 17:51–5. doi: 10.7314/APJCP.2016.17.1.51

112. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by Flavonoids from Pistacia integerrima. Asian Pac J Cancer Prev. (2016) 17:51–5. doi: 10.7314/APJCP.2016.17.1.51

113. Li S, Zhao Q, Wang B, Yuan S, Wang X, Li K. Quercetin reversed MDR in KB/VCR oral cancer cells. Mol Med Rep. (2013) 8:1883–7. doi: 10.3892/mmr.2013.1742

114. Wang ZD, Wang RZ, Xia YZ, Kong LY, Yang L. Reversal of multidrug resistance by icarin in doxorubicin-resistant human osteosarcoma cells. Chin J Nat Med. (2014) 16:210–8. doi: 10.11643/s11095-008-9583-6

115. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-kappaB activation and antioxidant defence. PLoS ONE. (2014) 9:e105076. doi: 10.1371/journal.pone.0105070

116. Wesolowska O, Wisniewski J, Sroda K, Krzewienko A, Bielawska-Pohl A, Paprocka M, et al. 4-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol. (2010) 644:32–40. doi: 10.1016/j.ejphar.2010.06.069

117. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by Flavonoids from Pistacia integerrima. Asian Pac J Cancer Prev. (2016) 17:51–5. doi: 10.7314/APJCP.2016.17.1.51

118. Chen Z, Huang C, Ma T, Jiang L, Tang L, Shi T, et al. Reversal of multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells. Mol Cancer Ther. (2018) 17:1195–206. doi: 10.1158/1535-7163.MCT-16-0515

119. Liu Y, Gong W, Yang ZY, Zhou XS, Gong C, Zhang TR, et al. Quercetin suppresses the metastatic ability of lung cancer through inhibiting Snail-dependent Akt activation and Snail-independent ADAM expression pathways. Biochim Biophys Acta Mol Cell Res. (2017) 1864:1746–58. doi: 10.1016/j.bbamcr.2016.07.017

120. Liu Y, Gong W, Yang ZY, Zhou XS, Gong C, Zhang TR, et al. Quercetin inhibits proliferation and drug resistance in KB/VCR oral cancer cells. Eur J Cell Biol. (2018) 97:671–80. doi: 10.1016/j.ejcb.2018.04.030

121. Mohana S, Ganesan M, Agilan B, Karthikeyan R, Srithar G, Beulah MR, et al. Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer. Mol Biosyst. (2016) 12:2458–70. doi: 10.1039/C6MB00187D

122. Chen Z, Huang C, Ma T, Jiang L, Tang L, Shi T, et al. Reversal effect of quercetin on multidrug resistance via P38/β-catenin pathway in hepatocellular carcinoma cells. Phytomedicine. (2018) 41:37–45. doi: 10.1016/j.phymed.2018.03.040

123. Liu L, Zhao Q, Wang R, Yuan S, Wang X, Li K. Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation. Phytother Res. (2018) 32:1530–6. doi: 10.1002/ptr.6081

124. Lu S, Li K, Zhang H, Dong Z. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. Anticancer Agents Med Chem. (2013) 13:552–5. doi: 10.2174/18717206131310020200

125. Yuan Z, Wang H, Hu Z, Huang Y, Yao F, Sun S, et al. Quercetin inhibits proliferation and drug resistance in KB/VCB oral cancer cells and enhances its sensitivity to vincristine. Nutr Cancer. (2015) 67:126–36. doi: 10.1080/01635581.2015.965334

126. Iriri M, Kubina R, Cochis A, Sorrentino R, Varoni EM, Kabala-Dzik A, et al. Rutin, a quercetin glycoside, restores chemosensitivity in human breast cancer cells. Phytother Res. (2017) 31:1529–38. doi: 10.1002/ptr.5878

127. Mukhtar H, Adhami VM, Siddiqi IA, Verma AK, Mukhtar H. Fisetin enhances chemotherapeutic effect of cabazitaxel against human prostate cancer cells. Mol Cancer Ther. (2016) 15:2863–74. doi: 10.1158/1535-7163.MCT-16-0515

128. Klimeszewska-Wawrzeszewska A, Hala-Wawrzeszewska, Tadrowski T, Gagat M, Grzanka D, Grzanka A. Paclitaxel and the dietary flavonoid fisetina synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 non-small cell lung cancer cells. Cancer Cell Int. (2016) 16:10. doi: 10.1186/s12935-016-0288-3

129. Sahu BD, Kalvava AK, Koneru M, Mahesh JK, Kuncha M, Rachamalla SS, et al. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κappaB activation and antioxidant defence. PLoS ONE. (2014) 9:e105076. doi: 10.1371/journal.pone.0105070
ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins. *Aptoptosis*. (2013) 18:618–26. doi: 10.1007/s10495-013-0808-8

145. Xu X, Zhang X, Zhang Y, Yang L, Liu Y, Huang S, et al. Wogonin reverses resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-kappaB inactivation. *Sci Rep*. (2017) 7:13490. doi: 10.1038/s41598-017-12823-8

146. Qian C, Wang Y, Zhong Y, Tang J, Zhang I, Li Z, et al. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells. *Free Radic. Res. (2014) 48:607–21.* doi: 10.3109/10715762.2014.897342

147. Laberge RM, Karwatsky I, Lincoln MC, Leimanis ML, Georges E. Modulation of GSH levels in ABCG1 expressing tumor cells triggers apoptosis through oxidative stress. *Biochem. Pharmacol*. (2007) 73:1727–37. doi: 10.1016/j.bcp.2007.02.005

148. Zhong Y, Zhang E, Sun Z, Zhou W, Li ZY, You Q, et al. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. *Mol. Carcinog*. (2013) 52:824–34. doi: 10.1002/mca.21921

149. Li Z, Zhang Y, Chen L, Li H. The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2. *Food. Funct.* (2018) 9:3018–27. doi: 10.1039/C8FO00333F

150. Palko-Labuz A, Sroda-Pomianek K, Uryga A, Kostrzewa-Suslow E, Michalak M. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Chian S, Thapa R, Chi Z, Wang XJ, Tang X. Luteolin inhibits the Nrf2 pathway. *Carcinog*. (2012) 33 (Suppl 1):E107–18. doi: 10.1002/cncr.22052

151. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, et al. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. *Cancer Chemother. Pharmacol*. (2010) 65:277–87. doi: 10.1007/s00280-009-1032-7

152. Kim HS, Wannatung T, Lee S, Yang WK, Chung SH, Lim JS, et al. Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HT116 colon cancer. *Aptoptosis*. (2012) 17:938–49. doi: 10.1007/s11049-012-9719-0

153. Wu B, Murali R, Kabey Y, French SW, Chiang YM, Liu S, et al. Baicalin targets GTPase-mediated autophagy to eliminate liver tumor initiating stem cell-like cells resistant to mTORC1 inhibition. *Hepatology*. (2018) 68:1726–40. doi: 10.1002/hep.30071

154. Erdogan S, Turkekul K, Serttas R, Erdogan Z. The natural flavonoid apigenin sensitizes human CD4(+) prostate cancer stem cells to cisplatin therapy. *Biomed. Pharmacother*. (2017) 88:210–7. doi: 10.1016/j.biopha.2017.01.056

155. Kim B, Jung N, Lee S, Sohng JK, Jung HJ. Apigenin inhibits cancer stem cell-like phenotypes in human glioblastoma cells via suppression of c-met signaling. *Phytother. Res.* (2016) 30:1833–40. doi: 10.1002/ptr.5689

156. Huyhn DL, Kwon T, Zhang JJ, Sharma N, Gera M, Ghosh M, et al. Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metalloproteinase-9 expression. *BMC Complement Altern. Med*. (2017) 17:304. doi: 10.1186/s12906-017-1788-y

157. Davies AH, Reipas K, Hu K, Berns R, Firmino N, Stratford AL, et al. Inhibition of RSK with the novel small-molecule inhibitor LJ508 overcomes chemoresistance by eliminating cancer stem cells. *Oncotarget*. (2015) 6:20570–7. doi: 10.18632/oncotarget.4135

158. Cao C, Sun L, Mo W, Sun L, Luo J, Yang Z, et al. Quercetin Mediates β-catenin in pancreatic cancer stem-like cells. *Pancras*. (2014) 44:1334–9. doi: 10.1097/MPA.0000000000000400

159. Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. *Semin Cancer Biol*. (2016) 40–41:192–208. doi: 10.1016/j.semcancer.2016.09.001

160. Atashpour S, Fouladdel S, Mohavbed TK, Barzegar E, Ghahremani MH, Ostad SN, et al. Quercetin induces cell cycle arrest and apoptosis in CD133(+) cancer stem cells of human colorectal HT29 cancer cell line and enhances anticaner effects of doxorubicin. *Iran J Basic Med Sci*. (2015) 18:635–43.

161. Tu SH, Ho CT, Liu ME, Huang CS, Chang HW, Chang CH, et al. Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. *Food. Chem*. (2013) 141:1553–61. doi: 10.1016/j.foodchem.2013.04.077

162. Srinivasan A, Thangavel C, Liu Y, Shoyele S, Den RB, Selvakumar P, et al. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer. *Mol. Carcinog*. (2016) 55:743–56. doi: 10.1002/mc.22318

163. Catanzaro D, Ragazzi E, Vianello C, Caparrotta L, Montopoli M. Cytotoxic effects of chemotherapeutic agents by suppression Nrf2-β-catenin signaling and reduces the hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis by inhibiting PI3K/Akt signaling pathway. *Mol. Carcinog*. (2014) 53 (Suppl 1):E107–18. doi: 10.1002/mca.22052

164. Liu Q, Zhu D, Hao B, Zhang Z, Tian Y. Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PPARα-mediated autophagy. *Cell. Mol. Biol*. (2018) 64:17–22. doi: 10.14715/cmb.2018.64.6

Yee et al. Flavonoids
189. Sun CY, Zhu Y, Li XF, Wang XQ, Tang LP, Su ZQ, et al. Scutellarin increases cell death in ovarian cancer cells. Frontiers in Oncology. www.frontiersin.org

182. Lirdprapamongkol K, Sakurai H, Abdelhamed S, Yokoyama S, Gao AC, Nadiminty N. Quercetin targets hnRNPA1 to induce cell death in human ovarian cancer cells. Anticancer Agents Med Chem. (2018) 18:901–10. doi: 10.1080/10420933.2018.1491828

179. Pan XW, Li L, Huang Y, Huang H, Xu DE, Gao Y, et al. Icaritin sensitizes paclitaxel-resistant ovarian cancer cells to cisplatin-induced apoptosis. Oncol Lett. (2017) 13:1314–20. doi: 10.3892/ol.2017.7399

180. Liang SQ, Marti TM, Dorn F, Froment L, Hall SR, Berezowska S, et al. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death Dis. (2015) 6:1824. doi: 10.1038/cddis.2015.195

181. Dia VP, Pangli P. Epithelial-to-mesenchymal transition in paclitaxel-resistant ovarian cancer cells is downregulated by luteolin. J Cell Physiol. (2017) 232:391–401. doi: 10.1002/jcp.25436

183. Yu S, Gong LS, Li NF, Pan YF, Zhang L. Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-kappaB and Bcl-2/Bax signaling pathways. Biomol Pharmacother. (2018) 97:213–24. doi: 10.1016/j.biopha.2017.10.059

184. Yang Z, Liu Y, Liao J, Gong C, Sun Z, Zhou X, et al. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. FEBS. (2015) 282:1111–25. doi: 10.1111/febs.13206

185. Li X, Huang JM, Wang JN, Xiong XK, Yang XI, Zou F. Combination of chrysophanol and genistein promotes the apoptosis of Hep G2 cells by up-regulating p53. Chem Biol Interact. (2015) 232:12–20. doi: 10.1016/j.cbi.2015.03.003

186. Liu R, Ji Pi, Liu B, Qiao H, Wang X, Zhou L, et al. Apigenin enhances the cisplatin cytotoxic effect through p53-mediated apoptosis. Oncol Lett. (2017) 13:1024–30. doi: 10.3892/ol.2016.5495

187. Xavier CP, Lima CF, Rohde M, Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol. (2011) 68:1449–57. doi: 10.1007/s00280-011-1641-9

188. Sun CY, Zhu Y, Li FE, Wang XQ, Tang LP, Su ZQ, et al. Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell lung cancer via ERK/p53 and c-met/AKT signaling pathways. Front Pharmacol. (2018) 9:9. doi: 10.3389/fphar.2018.00092

189. Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, Sarkar FH. Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res. (2008) 1:9. doi: 10.1186/1757-2215-1-9

190. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. (2005) 65:6934–42. doi: 10.1158/0008-5472.CAN-04-4604

191. Banerjee S, Zhang Y, Ali S, Bhuyan M, Wang Z, Chiao P, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. (2005) 65:9604–72. doi: 10.1158/0008-5472.CAN-05-1330

192. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S, et al. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer. (2011) 128:1240–50. doi: 10.1002/ijc.25658

193. Zheng B, Shi ZL, Liu B, Yan XB, Feng J, Tao HM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs. (2010) 21:288–96. doi: 10.1097/CAD.0b013e32833da17

194. Shen J, Tai YC, Zhou J, Stephen WC, Cheang PT, Fred WW, et al. Synergistic anti-leukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol. (2007) 35:75–83. doi: 10.1016/j.exphem.2006.09.007

195. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. Cancer Lett. (2011) 301:75–84. doi: 10.1016/j.canlet.2010.10.022

196. Sziliszka E, Czuba ZP, Mertas A, Paradyasz A, Krol W. The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis. Urol Oncol. (2013) 31:331–42. doi: 10.1016/j.urolonc.2011.01.019

197. Lee KT, Sohn IC, Kim YK, Choi JH, Choi JW, Park HJ, et al. Tectorigenin, an isoflavone of Pueraria thumbergiana Benth., induces differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biof Farm Bull. (2001) 24:1117–21. doi: 10.1248/bfb.24.1117
215. Zhao Y, Tian B, Wang Y, Ding H. Kaempferol sensitizes human ovarian cancer cells-OVCA-3 and SKOV-3 to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis via JNK/ERK-CHOP pathway and up-regulation of death receptors 4 and 5. *Med Sci Monit.* (2017) 23:1096–105. doi: 10.12659/MSM.920352

216. Siegelin MD, Reuss DE, Habel A, Herold-Mende C, von Deimling A. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. *Mol Cancer Ther.* (2008) 7:3566–74. doi: 10.1158/1535-7163.MCT-08-0236

217. Wu X, Zhang H, Salmani JM, Fu R, Chen B. Advances of wogonin, an anti-cancer flavonoid. *Curne Q, Yang DH, Chen ZS. Special issue: natural products: anticancer and Beyond. *Molecules.* (2018) 23:1246–9. doi: 10.3390/molecules23061246

218. Kim EH, Jang H, Shin D, Baek SH, Roh JL. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. *Apoptosis.* (2016) 21:1269–78. doi: 10.1007/s10495-016-1284-8

219. Dury L, Nasr R, Lorendeau D, Comsa E, Wong I, Zhu X, et al. Flavonoid dimers are highly potent killers of multidrug resistant cancer cells overexpressing MRP1. *Biochem Pharmacol.* (2017) 124:10–8. doi: 10.1016/j.bcp.2016.10.013

220. Russo GL, Russo M, Spagnuolo C. The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. *Food Funct.* (2014) 5:2393–401. doi: 10.1039/C4FF00413B

221. Shu X, Xie B, Liang Z, Chen J. Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met. *Oncol Lett.* (2018) 15:2252–8. doi: 10.3892/ol.2017.7561

222. Yang DH, Chen ZS. Special issue: natural products: anticancer and Beyond. *Apoptosis.* (2016) 23:1246–9. doi: 10.3390/molecules23061246

223. Kim JH, Kim MJ, Choi KC, Son J. Quercetin sensitizes pancreatic cancer cells to apoptosis induced by TRAIL through the JNK signaling pathway. *Cell Mol Biol.* (2015) 61:233–7.

224. Rong LW, Wang RX, Zheng XL, Feng XQ, Zhang L, Zhang L, et al. Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition. *Oncol Lett.* (2017) 13:5028–34. doi: 10.3892/ol.2017.6059

225. Priyadarshani G, Amrutkar S, Nayak A, Banerjee UC, Kundu CN, Guchhait SK. Targeting cancer cell mitochondria as a multi-factorial drug resistant cancer cells. *J Buon.* (2016) 21:43–54. doi: 10.1016/j.ejmech.2016.06.024

226. Tsuchiya H. Membrane interactions of phytochemicals as their molecular mechanism applicable to the discovery of drug leads from plants. *Molecules.* (2015) 20:18923–66. doi: 10.3390/molecules20118923

227. Kuete V, Sandjo LP, Djouessi DE, Zeino M, Kwamou GM, Ngadjui B, et al. Cytotoxic flavonoids and isoflavonoids from *Euphorbia sinica* signally regulates multi-drug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemo-sensitivity in resistant cancer cell lines. *Apoptosis.* (2016) 23:1246–9. doi: 10.3390/molecules23061246

228. Margina D, Ilie M, Manda G, Neagoe I, Mocanu M, Ionescu D, et al. Flavonoids and flavonoid dimers: highly potent killers of multidrug-resistant cancer cells overexpressing MRP1. *Biochem Pharmacol.* (2017) 124:10–8. doi: 10.1016/j.bcp.2016.10.013

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Ye, Liu, Shen, Li, Hao, Han and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.